[1] Poppe MM, Le-Rademacher JJ, Haffty BG, et al. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). J Clin Oncol. 2026(2026-10-12 在线). doi:10.1200/JCO-26-00474. PMID: 42863096
[2] Offersen BV, Alsner J, Høgsbjerg K, et al. Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. J Clin Oncol. 2026;44(24):2278-2289. doi:10.1200/JCO-25-02705. PMID: 42492022
[3] Wang X, Zhang X, Chen X, et al. Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial. J Clin Oncol. 2026(2026-10-19 在线). doi:10.1200/JCO-25-02843. PMID: 42896129
[4] Sun GY, Chen SY, Tang Y, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2026;27(10):1249-1259. doi:10.1016/S1470-2045(26)00297-4. PMID: 42805199